Sponsor Pipeline

REGENXBIO Inc. Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
6
Active Trials
0
Recruiting
3
Phase 3
1
Disease Areas
4
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-07-22 NCT05693142
AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy…
overall status: Recruiting → Active, Not Recruiting
2026-07-22 NCT05693142
AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy…
Trial sites expanded: 17 -> 23 locations
2026-07-22 NCT05693142
AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy…
date change Primary completion pushed: 2026-08 -> 2026-09
2026-07-22 NCT05693142
AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy…
date change Completion moved earlier: 2028-08 -> 2028-06
Active Trials by Phase
Phase 3
1
Phase 2/3
2
Not specified
3
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT07236606 RGX-121-3102 Gene Therapy in Participants With MPS II (Hunter Syndrome) MPS II Active, Not Recruiting
Phase 2/3
NCT03566043 CAMPSIITE™ RGX-121 Gene Therapy in Subjects With MPS II (Hunter Syndrome) Mucopolysaccharidosis Type II (MPS II) Active, Not Recruiting
NCT05693142 AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy… Duchenne Muscular Dystrophy Active, Not Recruiting
Not specified
NCT06491927 Long Term Follow-up for RGX-202 Duchenne Muscular Dystrophy Enrolling by Invitation
NCT06103487 Long Term Follow-Up for RGX-111 Mucopolysaccharidosis I Enrolling by Invitation
NCT05683379 AFFINITY BEYOND: Anti-AAV8 Antibody Assessment Study of Males With DMD Duchenne Muscular Dystrophy Active, Not Recruiting
Disease Areas
Get alerts when REGENXBIO Inc.'s trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free